Ginkgo EGb 761 240mg, 24-Week Frontal Lobe Blood Flow +14% with Cognitive Score Improvement
WELLNESS

Ginkgo EGb 761 240mg, 24-Week Frontal Lobe Blood Flow +14% with Cognitive Score Improvement

By Maya · · Frontiers in Aging Neuroscience
KO | EN

A multinational RCT of standardized Ginkgo extract EGb 761 at 240 mg/day for 24 weeks in mild cognitive impairment patients has been published. It is the first clinical trial validating frontal lobe cerebral blood flow improvement and cognitive score gains simultaneously.

Clinical Design and Results

A multinational, multicenter, double-blind, placebo-controlled RCT randomized 410 adults aged 60~80 with mild cognitive impairment (MCI) 1:1 to EGb 761 240 mg/day or placebo. After 24 weeks, the primary endpoint was change in ADAS-Cog (Alzheimer’s Disease Assessment Scale-Cognitive subscale); the secondary endpoint was regional cerebral blood flow measured by arterial spin labeling (ASL) MRI.

The EGb 761 arm showed ADAS-Cog -2.4 points versus placebo -0.6 points, a between-group difference of -1.8 (95% CI -2.4 to -1.2, p<0.001), exceeding the clinically meaningful threshold of -1.5. Frontal-region cerebral blood flow rose +14% (absolute +6.2 ml/100g/min) in the EGb 761 arm versus +1.2% with placebo. The temporal hippocampal region also showed +9% improvement.

Why Molecular Standardization Matters

EGb 761 is not raw ginkgo leaf powder. It is a standardized extract containing 24% flavone glycosides (quercetin, kaempferol, isorhamnetin glycosides) and 6% terpene lactones (ginkgolides A, B, C, bilobalide). This standardization ratio is the molecular signature of clinical efficacy.

Flavone glycosides drive antioxidant activity plus endothelial NO synthase (eNOS) activation, producing vasodilation. Among the terpene lactones, ginkgolide B antagonizes platelet activating factor (PAF), inhibiting platelet aggregation. These two mechanisms combine to improve microvascular flow at clinically measurable levels.

EGb 761 also stabilizes mitochondrial membranes and attenuates glutamate-mediated neurotoxicity, providing neuroprotective effects. Cognitive improvements begin around week 6 and stabilize at weeks 12~24.

Clinical Application

  • Standard dose: 120~240 mg/day, split (morning + evening) or single dose
  • Standardization markers: confirm 24% flavone glycosides + 6% terpene lactones on label
  • Clinical timing: onset week 6, stabilization weeks 12~24
  • Caution: bleeding risk increases with anticoagulants (warfarin, DOACs) or antiplatelets (aspirin, clopidogrel). Discontinue 7~14 days before surgery
  • Side effects: gastrointestinal discomfort, headache (first two weeks), rare rash

A 24-week +14% frontal blood flow with ADAS-Cog -2.4 points represents some of the most consistent data among non-pharmaceutical supplement RCTs in mild cognitive impairment. While not a head-to-head comparison with prescription drugs like donepezil or memantine, EGb 761 is establishing itself as a molecular matrix option for early-stage cognitive decline.

EGb 761 works alone but shows clinically consistent synergy when combined with antioxidant/vascular-protection matrix members (Pycnogenol, cocoa flavanols, citicoline). It is one of the core molecules of the cerebral and microcirculation natural matrix.